Literature DB >> 2836568

1H and 13C nuclear magnetic resonance studies of plasma from patients with primary intracranial neoplasms.

J Peeling1, G Sutherland, K Marat, E Tomchuk, E Bock.   

Abstract

Plasma from patients with malignant and benign primary intracranial neoplasms and from healthy control subjects has been examined using proton (1H) and carbon-13 nuclear magnetic resonance (NMR) spectroscopy. Some features in the spectra of plasma from patients with malignant tumors differ significantly (p less than 0.01) from the corresponding features in the spectra of plasma from control subjects and from patients with benign tumors. The NMR spectral parameters vary consistently with the Kernohan grade of astrocytoma, which may suggest that they give a measure of tumor growth kinetics. The observed spectral differences are shown to be due to elevated levels of monounsaturated and polyunsaturated fatty acid residues in the plasma of cancer patients. It is proposed that these lipid residues arise from cell membranes shed from cells in growing tumors. The ability to follow tumor growth kinetics directly may be of considerable importance in elucidating the effects of primary intracranial neoplasm therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836568     DOI: 10.3171/jns.1988.68.6.0931

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

1.  Human colorectal cancers display abnormal Fourier-transform infrared spectra.

Authors:  B Rigas; S Morgello; I S Goldman; P T Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  [13C]-nuclear magnetic resonance spectral profiles of serum from normal and Echinococcus granulosus-infected mice: a kinetic study.

Authors:  G Denegri; J Perez-Serrano; N Casado; F Rodriguez-Caabeiro
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

Review 3.  Imaging the adult brain.

Authors:  I Moseley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

4.  Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.

Authors:  P A Pasanen; R Kauppinen; M J Eskelinen; K P Partanen; P H Pikkarainen; E M Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Nuclear magnetic resonance and lipids of the plasma from patients with intracranial tumours.

Authors:  S Pomeranz; E Segal; E Ashkenazi; Y Hite; S Constantini
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

6.  Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.

Authors:  T Engan; J Krane; D C Johannessen; P E Lønning; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.

Authors:  E T Fossel; F M Hall; J McDonagh
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

8.  Magnetic resonance spectroscopy for the study of cns malignancies.

Authors:  Victor Ruiz-Rodado; Jeffery R Brender; Murali K Cherukuri; Mark R Gilbert; Mioara Larion
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2020-12-02       Impact factor: 9.795

9.  Failure to detect early breast cancer using in vitro nuclear magnetic resonance spectroscopy of plasma.

Authors:  L Holmberg; U Jakobsson; A Berglund; H O Adami
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.